Back to mobile site

Piper Sandler Reiterates Overweight Rating on Arcturus Therapeutics (ARCT)

July 15, 2024 8:43 AM EDT Send to a Friend
Piper Sandler analyst Yasmeen Rahimi reiterated an Overweight rating and $140.00 price target on Arcturus Therapeutics (NASDAQ: ARCT).The analsyt commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login